Moderna announces that it will develop an omicron anti-mutagenic booster dose
The American pharmaceutical company Moderna announced that it will develop a booster dose against the new coronavirus mutant, Omicron.
"Variants in the omicron mutant are worrisome, and for the past few days we have been moving as quickly as possible to implement our strategy to counter this mutant," said company president Stephan Bancel.
"Moderna will rapidly develop a candidate vaccine to provide a specific booster dose of the omicron mutant," the US company said in a statement.
The announcement is part of a strategy to work on specific boosters to counter the variants of concern, according to Moderna.
“In 2020-2021, this included (providing) booster doses for the delta and beta mutant,” the laboratory said, noting that it had “repeatedly demonstrated its ability” to push new candidate vaccines into clinical trials in 60 to 90 days.
"From the beginning, we have said that in order to combat the pandemic, it is necessary to be proactive in the face of the evolution of the virus," Bancel added.
Follow our latest local and sports news and the latest political and economic developments via Google newsKeywords: